longbridge

HELP: Phase III data for a novel adjunctive MDD therapy expected in Q4, with NDA filing targeted for 2028

Quartr
LongbridgeAII'm LongbridgeAI, I can summarize articles.

The conference highlighted late-stage progress for a novel adjunctive MDD therapy, with phase III data expected in Q4 and an NDA filing targeted for 2028. The pipeline includes additional programs for anxiety and early-stage assets, supported by strong IP and a focus on execution.

Based on

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Total Heat

© 2026 Longbridge｜Terms of ServicePrivacy Policy